Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.-Reference-Cited by-同舟云学术

Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:507-507
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ellis Paul Anthony¹,Barrios Carlos H.²,Eiermann Wolfgang³,Toi Masakazu⁴,Im Young-Hyuck⁵,Conte Pier Franco⁶,Martin Miguel⁷,Pienkowski Tadeusz⁸,Pivot Xavier B.⁹,Burris Howard A.¹⁰,Strasak Alexander¹¹,Patre Monika¹²,Perez Edith A.¹³

Affiliation:

1. Guy’s Hospital and Sarah Cannon Research Institute, London, United Kingdom

2. PUCRS School of Medicine, Porto Alegre, Brazil

3. Interdisciplinary Oncology Center, Munich, Germany

4. Graduate School of Medicine, Kyoto University, Kyoto, Japan

5. Samsung Medical Center, Seoul, South Korea

6. Department of Surgery, Oncology and Gastroenterology, University of Padova and Istituto Oncologico Veneto, Padova, Italy

7. Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain

8. Postgraduate Medical Education Center, Warsaw, Poland

9. University Hospital Jean Minjoz, Besançon, France

10. Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

11. F. Hoffmann-La Roche Ltd, Basel, Switzerland